Population Pharmacokinetic Analyses and Model Validation of Tolvaptan in Subjects With Autosomal Dominant Polycystic Kidney Disease

Tolvaptan is the first approved drug treatment to slow kidney function decline in adults at risk of rapidly progressing autosomal dominant polycystic kidney disease (ADPKD). The objective is to develop (1091 subjects, 7335 observations) and validate (678 subjects, 3012 observations) a population pha...

Descripción completa

Detalles Bibliográficos
Autores principales: Lanke, Shankar, Shoaf, Susan E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Pharmacometrics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6590359/
https://www.ncbi.nlm.nih.gov/pubmed/30618157
http://dx.doi.org/10.1002/jcph.1370

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6590359/
https://www.ncbi.nlm.nih.gov/pubmed/30618157
http://dx.doi.org/10.1002/jcph.1370

Ejemplares similares